Colorectal cancer, Vitamin D and microbiota: A double-blind Phase II randomized trial (ColoViD) in colorectal cancer patientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This double-blind phase II randomized trial (ColoViD) examined the interplay between vitamin D supplementation, gut microbiota, and colorectal cancer (CRC) outcomes. Patients who had completed standard CRC treatment received either 2000 IU/day of vitamin D or placebo for one year. Fecal samples were collected before and after treatment and analyzed by shotgun metagenomic sequencing to identify taxa and pathways associated with supplementation. The study also used mediation analysis to test whether microbiota changes explained vitamin D's effect on blood 25(OH)D levels, and a Cox model to examine disease-free survival.
Who was studied?
The trial enrolled 74 CRC patients who had completed standard treatment, of whom 60 were ultimately analyzed. All participants had undergone fecal sampling and blood 25(OH)D testing at baseline and after one year of supplementation or placebo. The abstract notes that sex differences in vitamin D levels, microbiota composition, and pathways were observed within this cohort.
What were the most important findings?
Overall microbial diversity did not differ between the vitamin D and placebo arms, with comparable changes in alpha diversity (Shannon p = 0.77, Simpson p = 0.63) and post-treatment beta diversity (p = 0.70). Despite this, post-treatment abundances of 63 taxa and 32 pathways differed significantly between arms. Notably, these 63 taxa were found to mediate the effect of vitamin D supplementation on 25(OH)D blood levels (p = 0.02), and sex-specific differences emerged in vitamin D levels, microbiota, and pathways.
What are the greatest implications of this study?
The findings suggest that vitamin D supplementation influences specific gut bacterial taxa and metabolic pathways even without altering overall community diversity, and that these taxa may partly govern how well vitamin D is absorbed or metabolized into its active blood form. This points to a bidirectional relationship between the gut microbiota and vitamin D status in CRC survivors that could inform future supplementation strategies. The observed sex differences further suggest that vitamin D-microbiota interactions may need to be considered separately for men and women in future research and clinical practice.